PROGRAM PLANNING COMMITTEE

Co-Chairmen

Martin H. Goldrosen
John H. Howell

Committee Members

David M. P. Thomson
William J. Halliday

PROGRAM

List of Participants .............................................................. 554
Introduction to the Leukocyte Adherence Inhibition Workshop.
  Gerald P. Murphy ............................................................... 555
Current Status of Leukocyte Adherence Inhibition.
  John H. Howell ................................................................. 556

SESSION I

Mechanism of the Leukocyte Adherence Inhibition Assay

Chairman: Suzanne Eccles

Co-Chairman: Dorothy Glaves

Historical Background and Aspects of the Mechanism of Leukocyte Adherence Inhibition.
  W. J. Halliday ................................................................. 558
Evaluation of the Microplate Leukocyte Adherence Inhibition Test and Its Reproducibility, Sensitivity, and Relationship to Other Tests of Cellular Immunity.
  Patrick G. Holt, Peter J. Fimmel, Lynette M. Finlay-Jones, and Robert L. Flower ................................. 564
Antigenic Specificity and Cellular Mechanisms in Leukocyte Adherence Inhibition Analysis of Immunity to Simple Proteins and Hapten-Protein Conjugates.
  Arnold Powell, Alice M. Sloss, R. Neal Smith, and Helen Murrell ...................................................... 570
Immunological Mechanisms of Tube Leukocyte Adherence Inhibition.
  D. M. P. Thomson and Norman Grosser ................................................. 576
Correlations between the Leukocyte Adherence Inhibition Microassay and in Vivo Tests of Transplantation Resistance.
  Stephen H. Leveson, John H. Howell, Norman S. Paolini, Mong H. Tan, Edward D. Holyoke, and Martin H. Goldrosen ...................................................... 582
Cellular and Humoral Factors Involved in the Mechanism of the Micro-Leukocyte Adherence Inhibition Reaction.
Cross-Reactivity between Bacillus Calmette-Guérin and Rous Virus-induced Sarcoma Detected in Rats by Tube Leukocyte Adherence Inhibition Assay.
  Vladimir Holan, Jitka Chutná, and Milan Hasek ...................................................... 593
Assessment of the Mechanism of the Leukocyte Adherence Inhibition Test.
  Alex W. Tong, Denis R. Burger, Patricia Finke, Carolyn Barney, Arthur A. Vandenbark, and R. Mark Vetto ... 597

SESSION II

Preparation and Characterization of Antigens Used in Leukocyte Adherence Inhibition Assays

Chairman: William J. Halliday

Co-Chairman: Martin H. Goldrosen

Evidence for the Expression of Human Tumor-specific Antigens Associated with β2-Microglobulin in Human Cancer and in Some Colon Adenomas and Benign Breast Lesions.
  D. M. P. Thomson, Donna N. Tataryn, Richard O’Connor, Joyce Rauch, Paula Friedlander, Phil Gold, and Joe Shuster ...................................................... 604
Characterization of Murine Tumor-associated Antigens by the Micro-Leukocyte Adherence Inhibition Assay.

John H. Howell, Anthony J. Russo, and Martin H. Goldrosen ............................................................... 612

Association of Melanoma Tumor Antigen Activity with \( \beta \)-Microglobulin.


SESSION III

Demonstration and Evaluation of Leukocyte Adherence Inhibition Assay

Chairman: Mitsuo Takasugi

Co-Chairman: James L. McCoy

Demonstration and Evaluation of the Leukocyte Adherence Inhibition Assay.

Martin H. Goldrosen ................................................................................................................................. 624

Hemocytometer Leukocyte Adherence Inhibition Technique.

Annette E. Maluish and W. J. Halliday ........................................................................................................ 625

Demonstration of Tube Leukocyte Adherence Inhibition Assay with Coded Samples of Blood.

D. M. P. Thomson ........................................................................................................................................ 627

Demonstration of the Microtest Version of the Leukocyte Adherence Inhibition Assay.

Martin H. Goldrosen, John H. Howell, and Edward D. Holyoke .................................................................. 630

SESSION IV

Detection and Monitoring of Human Cancer with Leukocyte Adherence Inhibition

Chairman: Mitsuo Takasugi

Co-Chairman: James L. McCoy

Evaluation of Micro-Leukocyte Adherence Inhibition as an Immunodiagnostic Test for Pancreatic Cancer.


Human Tumor-specific Immunity Assayed by a Computerized Tube Leukocyte Adherence Inhibition.

D. M. P. Thomson, Donna N. Tataryn, Marvin Lopez, Rosemarie Schwartz, and John K. MacFarlane ................................................................................................................................................................................. 638

Experiences with Leukocyte Adherence Inhibition in Human Cancer.

Annette E. Maluish ........................................................................................................................................ 644

The Need to Establish Whether the Leukocyte Adherence Inhibition Test Is a Reliable Assay of Tumor Immunity in Humans.

Karl Erik Hellstrom and Ingegerd Hellstrom ................................................................................................. 649

Monitoring of Antitumor Immunity in Patients with Larynx Cancer by Tube Leukocyte Adherence Inhibition Assay.

Vladimir Holan, Otakar Sibl, and Milan Hasek .............................................................................................. 651


Tore Sanner, Ivar Brennhovd, Ingrid Christensen, Ole Jorgensen, and Stein Kvaløy ........................................................................................................................................................................................................ 654

Immunological Basis of Close-Contact Sensitization to Osteosarcoma.

Arnold Powell, Alice M. Sloss, and John T. Makley ....................................................................................... 658

Summary and Future Prospects of Leukocyte Adherence Inhibition.

Martin H. Goldrosen ...................................................................................................................................... 660

FEBRUARY 1979
Cancer Research

39 (2 Part 2)


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/39/2_Part_2.citation

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.